(Q43690747)

English

HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.

scientific article published in April 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Robert M. Lafrenie

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

author name string

Bewick M

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Conlon M

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Gerard S

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Lee H

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Parissenti AM

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Zhang L

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Glück S

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

language of work or name

0 references

publication date

1 April 2001

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

27

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

847-853

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703005

0 references

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

21 January 2018

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

21 January 2018

Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

21 January 2018

Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

21 January 2018

Paclitaxel-containing high-dose chemotherapy in high-risk breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

21 January 2018

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

21 January 2018

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

21 January 2018

Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel administered on a weekly basis for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

7 January 2021

based on heuristic

inferred from DOI database lookup

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

7 January 2021

based on heuristic

inferred from DOI database lookup

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

7 January 2021

based on heuristic

inferred from DOI database lookup

The neu-oncogene product in serum and tissue of patients with breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

7 January 2021

based on heuristic

inferred from DOI database lookup

c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

7 January 2021

based on heuristic

inferred from DOI database lookup

C-erb-b2/int-2 amplification appears faster in breast-cancer patients receiving second-line endocrine treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

7 January 2021

based on heuristic

inferred from DOI database lookup

ElevatederbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703005

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1703005

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Dimensions Publication ID

0 references

release_ffkikymnq5grjiususg7wk7yry

1 reference

https://api.fatcat.wiki/v0/release/ffkikymnq5grjiususg7wk7yry

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11477443%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43690747&oldid=2103279582"